RT Journal Article
T1 Tripalmitin nanoparticle formulations significantly enhance paclitaxel antitumor activity against breast and lung cancer cells in vitro.
A1 Leiva, Maria Carmen
A1 Ortiz, Raul
A1 Contreras-Caceres, Rafael
A1 Perazzoli, Gloria
A1 Mayevych, Iryna
A1 Lopez-Romero, Juan Manuel
A1 Sarabia, Francisco
A1 Baeyens, Jose Manuel
A1 Melguizo, Consolación
A1 Prados, Jose
K1 Molecular medicine
K1 Oncology
AB Paclitaxel (PTX) is one of the drugs of choice in the treatment of breast and lung cancer. However, its severe side effects, including mielosuppression, cardiotoxicity and neurotoxicity, frequently cause treatment to be discontinued. Solid lipid nanoparticles (NPs) of glyceril tripalmitate (tripalmitin) loaded with PTX (Tripalm-NPs-PTX) including modifications by the addition of hexa(ethylene glycol), β-cyclodextrin and macelignan were developed. All NPs-PTX formulations displayed excellent hemocompatibility and significantly enhanced PTX antitumor activity in human breast (MCF7, MDAMB231, SKBR3 and T47D) and lung (A549, NCI-H520 and NCI-H460) cancer cells. Tripalm-NPs-PTX decreased PTX IC50 by as much as 40.5-fold in breast and 38.8-fold in lung cancer cells and Tripalm-NPs-PTX macelignan inhibited P-glycoprotein in resistant tumor cells. In addition, Tripalm-NPs-PTX significantly decreased the volume of breast and lung multicellular tumor spheroids that mimics in vivo tumor mass. Finally, Tripalm-NPs-PTX decreased the PTX IC50 of cancer stem cells (CSCs) derived from both lung and breast cancer cells (6.7- and 14.9-fold for MCF7 and A549 CSCs, respectively). These results offer a new PTX nanoformulation based on the use of tripalmitin which improves the antitumor activity of PTX and that may serve as an alternative PTX delivery system in breast and lung cancer treatment.
PB Nature Publishing Group
YR 2017
FD 2017-09-29
LK http://hdl.handle.net/10668/11693
UL http://hdl.handle.net/10668/11693
LA en
NO Leiva MC, Ortiz R, Contreras-Cáceres R, Perazzoli G, Mayevych I, López-Romero JM, et al. Tripalmitin nanoparticle formulations significantly enhance paclitaxel antitumor activity against breast and lung cancer cells in vitro. Sci Rep. 2017 Oct 18;7(1):13506.
NO This investigation was funded by Consejería de Salud de la Junta de Andalucía through project PI-0476–2016, Consejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía through project P11-CTS-7649 and by Granada University project PP2015-13 and financial Groups 09/112016. We also thank the financial support to CICYT, Spain, Project CTQ13-48418-P, CTQ14-60233-R and CTQ16-76311-R, FEDER funds. RC-C acknowledges to the Andalucía Tech program “U-mobility” co-financed by University of Málaga and the European Community’s Seventh Framework Program under Grant Agreement No 246550. The authors wish to express their gratitude to Dr. Antonio Martinez-Feréz from the Department of Chemical Engineering, Science Faculty, University of Granada, (Spain) for her help in the nanoparticle synthesis and Dr. G. Ortiz Ferron (CIC, University of Granada, Spain) for his skillful assistance with experiments. We thanks the research grant (FPU) from Ministerio de Educacion Cultura y Deporte.
DS RISalud
RD Apr 17, 2025